Solventum (NYSE:SOLV) Releases FY 2026 Earnings Guidance

Solventum (NYSE:SOLV) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 7.100-7.200 for the period, compared to the consensus estimate of 6.550. The company issued revenue guidance of -.

Solventum Stock Performance

Shares of NYSE SOLV traded down $0.68 during trading hours on Wednesday, reaching $87.26. The stock had a trading volume of 1,552,465 shares, compared to its average volume of 1,413,710. The company has a market cap of $15.11 billion, a price-to-earnings ratio of 10.69, a PEG ratio of 1.36 and a beta of 0.60. Solventum has a twelve month low of $62.38 and a twelve month high of $88.65. The business’s fifty day moving average is $78.87 and its two-hundred day moving average is $74.31. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.90 by $0.65. The firm had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.15 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. As a group, research analysts expect that Solventum will post 6.58 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on SOLV. Weiss Ratings upgraded shares of Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, July 17th. Stifel Nicolaus cut their price target on shares of Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. UBS Group raised Solventum from a “neutral” rating to a “buy” rating and set a $95.00 price objective on the stock in a report on Tuesday, July 28th. Wedbush assumed coverage on Solventum in a report on Friday, May 15th. They issued an “outperform” rating and a $94.00 target price for the company. Finally, Piper Sandler cut their target price on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Seven equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Solventum presently has an average rating of “Hold” and a consensus target price of $86.00.

Institutional Trading of Solventum

Large investors have recently made changes to their positions in the business. CrossGen Wealth LLC bought a new position in shares of Solventum in the fourth quarter valued at about $25,000. Measured Wealth Private Client Group LLC bought a new stake in Solventum during the 3rd quarter worth about $25,000. CYBER HORNET ETFs LLC acquired a new stake in Solventum in the 2nd quarter valued at about $28,000. MUFG Securities EMEA plc acquired a new stake in Solventum in the 2nd quarter valued at about $31,000. Finally, State of Wyoming bought a new position in shares of Solventum in the second quarter worth about $33,000.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.